FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093157092> ?p ?o ?g. }

• W2093157092 endingPage "71" @default.
• W2093157092 startingPage "71" @default.
• W2093157092 abstract "Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder that originates from antigen-experienced B lymphocytes that do not die and hence accumulate due to external survival signals or undergo apoptosis and are replenished by proliferating precursors. These neoplastic lymphocytes exhibit a characteristic immunophenotype of CD5(+)/CD19(+)/CD20(+)/HLA-DR+/CD23(+)/sIgdim. Thus, the CD20 antigen has been an appealing target for therapy. The introduction of the monoclonal antibody rituximab (anti-CD20) enabled an outstanding advance in CLL treatment. The introduction of this monoclonal antibody into chemotherapy regimens has dramatically improved complete response rates and progression-free survival in patients with both untreated and relapsed CLL. Although only preliminary data from phase III confirmatory trials have been reported, the FCR regimen, which combines fludarabine and cyclophosphamide with rituximab, is currently the most effective treatment regimen for CLL patients, and has also been demonstrated to significantly improve overall survival. The success of rituximab and the identification of other CLL lymphocyte surface antigens have spurred the development of a multitude of monoclonal antibodies targeting distinct proteins and epitopes in an attempt to target CLL cells more effectively." @default.
• W2093157092 created "2016-06-24" @default.
• W2093157092 creator A5008069105 @default.
• W2093157092 creator A5010613445 @default.
• W2093157092 creator A5016021915 @default.
• W2093157092 creator A5022153283 @default.
• W2093157092 creator A5038127900 @default.
• W2093157092 creator A5063863499 @default.
• W2093157092 creator A5071487461 @default.
• W2093157092 creator A5088942860 @default.
• W2093157092 creator A5089717138 @default.
• W2093157092 date "2010-03-01" @default.
• W2093157092 modified "2023-09-27" @default.
• W2093157092 title "Rituximab for the treatment of patients with chronic lymphocytic leukemia" @default.
• W2093157092 cites W103174640 @default.
• W2093157092 cites W1643400449 @default.
• W2093157092 cites W1685882185 @default.
• W2093157092 cites W1915689252 @default.
• W2093157092 cites W1954038871 @default.
• W2093157092 cites W1978235999 @default.
• W2093157092 cites W1988217711 @default.
• W2093157092 cites W1994244606 @default.
• W2093157092 cites W1996008853 @default.
• W2093157092 cites W2001014409 @default.
• W2093157092 cites W2001850157 @default.
• W2093157092 cites W2001934131 @default.
• W2093157092 cites W2008542227 @default.
• W2093157092 cites W2024303920 @default.
• W2093157092 cites W2029414180 @default.
• W2093157092 cites W2029903885 @default.
• W2093157092 cites W2034168567 @default.
• W2093157092 cites W2044360617 @default.
• W2093157092 cites W2046534114 @default.
• W2093157092 cites W2047982141 @default.
• W2093157092 cites W2052346599 @default.
• W2093157092 cites W2052722931 @default.
• W2093157092 cites W2057796652 @default.
• W2093157092 cites W2066388140 @default.
• W2093157092 cites W206701898 @default.
• W2093157092 cites W2070193300 @default.
• W2093157092 cites W2072620152 @default.
• W2093157092 cites W2073556842 @default.
• W2093157092 cites W2073873436 @default.
• W2093157092 cites W2077450104 @default.
• W2093157092 cites W2082635925 @default.
• W2093157092 cites W2097852595 @default.
• W2093157092 cites W2104940816 @default.
• W2093157092 cites W2105044162 @default.
• W2093157092 cites W2107567250 @default.
• W2093157092 cites W2112212243 @default.
• W2093157092 cites W2112476236 @default.
• W2093157092 cites W2116262245 @default.
• W2093157092 cites W2117648265 @default.
• W2093157092 cites W2118292865 @default.
• W2093157092 cites W2125134816 @default.
• W2093157092 cites W2129041705 @default.
• W2093157092 cites W2132095426 @default.
• W2093157092 cites W2137804513 @default.
• W2093157092 cites W2138404218 @default.
• W2093157092 cites W2140791665 @default.
• W2093157092 cites W2141682526 @default.
• W2093157092 cites W2141880470 @default.
• W2093157092 cites W2142741025 @default.
• W2093157092 cites W2145604368 @default.
• W2093157092 cites W2152011817 @default.
• W2093157092 cites W2161926682 @default.
• W2093157092 cites W2162125647 @default.
• W2093157092 cites W2163348695 @default.
• W2093157092 cites W2165346275 @default.
• W2093157092 cites W2169386895 @default.
• W2093157092 cites W2275948481 @default.
• W2093157092 cites W2293559777 @default.
• W2093157092 cites W2315168692 @default.
• W2093157092 cites W2326175431 @default.
• W2093157092 cites W2397284397 @default.
• W2093157092 cites W2417730399 @default.
• W2093157092 cites W24657089 @default.
• W2093157092 cites W2535516671 @default.
• W2093157092 cites W2565132879 @default.
• W2093157092 cites W2979568374 @default.
• W2093157092 cites W2979771654 @default.
• W2093157092 cites W33733012 @default.
• W2093157092 cites W592648520 @default.
• W2093157092 cites W60759546 @default.
• W2093157092 cites W85464595 @default.
• W2093157092 cites W96780237 @default.
• W2093157092 cites W2101252134 @default.
• W2093157092 doi "https://doi.org/10.2147/cmar.s5621" @default.
• W2093157092 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3004569" @default.
• W2093157092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21188098" @default.
• W2093157092 hasPublicationYear "2010" @default.
• W2093157092 type Work @default.
• W2093157092 sameAs 2093157092 @default.
• W2093157092 citedByCount "4" @default.
• W2093157092 countsByYear W20931570922012 @default.
• W2093157092 countsByYear W20931570922016 @default.
• W2093157092 crossrefType "journal-article" @default.
• W2093157092 hasAuthorship W2093157092A5008069105 @default.

• next